Erlotinib treatment

7 trials

Sponsors

Central Japan Lung Study Group (CJLSG), Department of Respirology/Division of Clinical Oncology, Graduate School of Medicine, Chiba University, Lung Oncology Group in Kyushu, Japan (LOGIK), Thoracic Oncology Research Group, NPO Thoracic Oncology Research Group

Conditions

Chemotherapy-treated recurrent non-small cell lung cancerNon small cell lung cancer with Epidermal Growth Factor Receptor mutationNon-small Cell Lung CancerNon-small cell lung cancerelderly patients with refractory or recurrent non-small cell lung cancer non-small cell lung cancer

Phase 2

A Phase II Study of Erlotinib for previously treated Non-small cell Lung Cancer Patients without Epidermal Growth Factor Receptor Mutation

Active, not recruitingJPRN-UMIN000002692

Central Japan Lung Study Group (CJLSG)Non-small cell lung cancer

Start: 2009-11-01Target: 54Updated: 2026-06-29

A Phase II Study of Erlotinib for previously treated Non-small cell Lung Cancer Patients with Epidermal Growth Factor Receptor Mutation

Active, not recruitingJPRN-UMIN000002716

Central Japan Lung Study Group (CJLSG)Non-small cell lung cancer

Start: 2009-11-01Target: 29Updated: 2026-06-29

Clinical relevance and biomarker search of erlotinib against chemotherapy-treated recurrent non-small cell lung cancer

Active, not recruitingJPRN-UMIN000002811

Department of Respirology/Division of Clinical Oncology, Graduate School of Medicine, Chiba UniversityChemotherapy-treated recurrent non-small cell lung cancer

Start: 2009-12-01Target: 46Updated: 2026-06-29

Multicenter Phase II study of erlotinib therapy in recurrent or advanced non-small cell lung cancer patients with Epidermal Growth Factor Receptor (EGFR) mutation

Active, not recruitingJPRN-UMIN000003270

Lung Oncology Group in Kyushu, Japan (LOGIK)Non small cell lung cancer with Epidermal Growth Factor Receptor mutation

Start: 2009-05-01Target: 26Updated: 2026-06-29

Multicenter PhaseII trial of erlotinib for elderly patients with advanced or recurrent non-small cell lung cancer.

Active, not recruitingJPRN-UMIN000003271

Lung Oncology Group in Kyushu, Japan (LOGIK)elderly patients with refractory or recurrent non-small cell lung cancer non-small cell lung cancer

Start: 2009-05-01Target: 44Updated: 2026-06-29

Multicenter Phase II study of erlotinib for advanced or recurrent non-small cell lung cancer with Epidermal Growth factor Receptor (EGFR) mutation (TORG0911)

Active, not recruitingJPRN-UMIN000003313

Thoracic Oncology Research GroupNon-small cell lung cancer

Start: 2010-03-01Target: 45Updated: 2026-06-29

A Prospective, Multi-center Phase II Trial on the Efficacy and Safety of Low-dose Erlotinib Monotherapy for Frail Patients with EGFR Mutation-positive, Non-small Cell Lung Cancer(TORG1425)

Active, not recruitingJPRN-UMIN000015949

NPO Thoracic Oncology Research GroupNon-small Cell Lung Cancer

Start: 2015-01-07Target: 80Updated: 2026-06-29

Related Papers

Low-Dose Erlotinib Treatment in Elderly or Frail Patients With <i>EGFR</i> Mutation–Positive Non–Small Cell Lung Cancer

JAMA Oncology2020-05-1546 citations

ABCB1 genetic polymorphism and pharmacokinetic analysis of low dose erlotinib in frail patients with EGFR mutation (mt)-positive, non-small cell lung cancer: TORG1425

Annals of Oncology2018-10-01